Loxo Oncology Inc (NASDAQ:LOXO) VP Jennifer Burstein sold 1,700 shares of the company’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $93.24, for a total value of $158,508.00. Following the completion of the transaction, the vice president now owns 1,700 shares of the company’s stock, valued at $158,508. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Jennifer Burstein also recently made the following trade(s):
- On Tuesday, January 16th, Jennifer Burstein sold 1,500 shares of Loxo Oncology stock. The shares were sold at an average price of $87.50, for a total value of $131,250.00.
- On Thursday, December 14th, Jennifer Burstein sold 1,700 shares of Loxo Oncology stock. The shares were sold at an average price of $83.27, for a total value of $141,559.00.
- On Monday, November 27th, Jennifer Burstein sold 1,700 shares of Loxo Oncology stock. The shares were sold at an average price of $74.82, for a total value of $127,194.00.
Loxo Oncology Inc (NASDAQ:LOXO) traded up $3.43 during trading on Wednesday, reaching $104.35. The company had a trading volume of 504,068 shares, compared to its average volume of 344,973. Loxo Oncology Inc has a 52-week low of $40.01 and a 52-week high of $108.50. The firm has a market capitalization of $2,812.33, a price-to-earnings ratio of -17.31 and a beta of 2.57.
LOXO has been the subject of several analyst reports. Zacks Investment Research lowered Loxo Oncology from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. William Blair initiated coverage on Loxo Oncology in a research note on Tuesday, November 28th. They issued an “outperform” rating for the company. BidaskClub upgraded Loxo Oncology from a “strong sell” rating to a “sell” rating in a research note on Tuesday, December 12th. JMP Securities upgraded Loxo Oncology from a “market perform” rating to an “outperform” rating and upped their target price for the company from $77.18 to $95.00 in a research note on Tuesday, November 14th. Finally, Citigroup dropped their target price on Loxo Oncology from $112.00 to $108.00 and set a “buy” rating for the company in a research note on Thursday, November 16th. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $97.33.
About Loxo Oncology
Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.
Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.